MANILA, Philippines – Synovate Healthcare, the health care specialist unit of global market research firm Synovate, announced that it has launched its newest syndicated therapy monitor focusing on the drug treatment of patients with hyperlipidaemia in the Asia-Pacific.
Hyperlipidaemia, a condition of abnormally high blood lipid levels, is closely associated with a significant increase in the risk of cardiovascular disease.
“Our new hyperlipidaemia monitor further strengthens Synovate Healthcare’s extensive syndicated products in the region, and also complements our diabetes monitor, which we launched in Asia in 2006,” said Pieter de Richter, Synovate Healthcare vice president of global therapy monitors.
The prevalence of hyperlipidaemia in Asia has been rising with changing lifestyles, and while statins continue to be the cornerstone of treatment, a number of new medications to treat the condition are currently in development.
The results from the first wave of Synovate’s hyperlipidaemia monitor in China, conducted in the fourth quarter of 2010, show that as many as 43 percent of Chinese patients on hypolipemics have concomitant type 2 diabetes.
As hyperlipidaemia rarely occurs in isolation and is usually part of a complex set of metabolic and cardiovascular disorders, 59 percent of Chinese patients on hypolipemics are also suffering from hypertension.
“Since these conditions are often interrelated, we also plan to launch a hypertension monitor in Asia later this year in order to help pharmaceutical companies and others dig even deeper into the complex treatment of these conditions,” said De Richter.
For more information on Synovate’s syndicated health care monitors, contact pieter.derichter@synovate.com. For more information on Synovate Healthcare, visit www.synovate.com/healthcare.